Drugs / amosartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02140489 | Feb → May 2014 | — | Hanmi Pharmaceutical Company Limited | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2014-11-28 | Hanmi Pharmaceutical Company Limited | Regulatory The new global anti-hypertension combination product ‘Amosartan’, obtained a patent in Japan hanmipharm.com ↗
Hanmi Pharm. Co., Ltd. (CEO: Gwan Sun Lee) disclosed on 27th that a new global anti-hypertension combination product, Amosartan, has obtained a composition patent (patented number: JP2011547746) in Japan. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2014-11-28 | Hanmi Pharmaceutical Company Limited | The new global anti-hypertension combination product ‘Amosartan’, obtained a patent in Japan hanmipharm.com ↗ |
| 2014-07-18 | Hanmi Pharmaceutical Company Limited | Hanmi science got patent for Amosartan in Europe hanmipharm.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | amosartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02140489 ↗ |
| Route | Oral | “amosartan and rosuvastatin, P.O” NCT02140489 ↗ |